Equities Research Analysts’ updated eps estimates for Thursday, September 7th:
Apple (NASDAQ:AAPL) had its hold rating reissued by analysts at KeyCorp.
Amgen (NASDAQ:AMGN) had its buy rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. The firm currently has a $203.00 target price on the stock.
Macquarie assumed coverage on shares of Peabody Energy (NASDAQ:BTUUQ). The firm issued a hold rating and a $30.00 target price on the stock.
Cabela’s (NYSE:CAB) had its buy rating reiterated by analysts at Forward View. Forward View currently has a $61.50 target price on the stock.
Avis Budget Group (NASDAQ:CAR) had its hold rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). Goldman Sachs Group, Inc. (The) currently has a $37.00 target price on the stock.
Donaldson (NYSE:DCI) had its hold rating reiterated by analysts at Oppenheimer Holdings, Inc..
WisdomTree Intl. LargeCap Div Fd (NYSEARCA:DOL) had its buy rating reissued by analysts at Canaccord Genuity. They currently have a $143.00 price target on the stock.
EXACT Sciences (NASDAQ:EXAS) had its buy rating reiterated by analysts at Canaccord Genuity. The firm currently has a $45.00 target price on the stock.
Alphabet (NASDAQ:GOOGL) had its buy rating reissued by analysts at SunTrust Banks, Inc.. The firm currently has a $1,100.00 target price on the stock.
Himax Technologies (NASDAQ:HIMX) had its sell rating reiterated by analysts at Oppenheimer Holdings, Inc.. They currently have a $4.00 price target on the stock.
Labrador Iron Ore Royalty Corporation (TSE:LIF) was upgraded by analysts at Scotiabank from a sector perform rating to an outperform rating. Scotiabank currently has C$23.00 price target on the stock, up from their previous price target of C$20.00.
Mgm China Hldgs Lt (NASDAQ:MCHVY) was upgraded by analysts at Deutsche Bank AG to a buy rating.
Microsoft Corporation (NASDAQ:MSFT) had its buy rating reiterated by analysts at Oppenheimer Holdings, Inc.. They currently have a $80.00 target price on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) had its buy rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They currently have a $70.00 target price on the stock.
Netflix (NASDAQ:NFLX) had its hold rating reissued by analysts at SunTrust Banks, Inc.. They currently have a $175.00 price target on the stock.
Nutanix (NASDAQ:NTNX) had its buy rating reiterated by analysts at Oppenheimer Holdings, Inc.. The firm currently has a $34.00 target price on the stock.
CIBC started coverage on shares of Pacira Pharmaceuticals (NASDAQ:PCRX). They issued a market perform rating on the stock.
CIBC started coverage on shares of Perrigo (NYSE:PRGO). The firm issued an outperform rating and a $88.00 target price on the stock.
Restaurant Brands International (TSE:QSR) (NYSE:QSR) was upgraded by analysts at CSFB from a neutral rating to an outperform rating.
Regeneron Pharmaceuticals (NASDAQ:REGN) had its buy rating reissued by analysts at Citigroup Inc.. The firm currently has a $575.00 price target on the stock.
Restoration Hardware Holdings (NYSE:RH) had its hold rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Silicon Graphics International Corp (NASDAQ:SGI) had its outperform rating reiterated by analysts at BMO Capital Markets. The firm currently has a $1.60 target price on the stock.
Peak Resorts (NASDAQ:SKIS) had its buy rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They currently have a $7.00 target price on the stock.
Sarepta Therapeutics (NASDAQ:SRPT) had its buy rating reiterated by analysts at Oppenheimer Holdings, Inc.. They currently have a $76.00 target price on the stock.
Trivago N.V. ADS (NASDAQ:TRVG) had its buy rating reissued by analysts at J P Morgan Chase & Co. They currently have a $16.00 price target on the stock.
Tesla (NASDAQ:TSLA) had its hold rating reissued by analysts at Morgan Stanley. They currently have a $317.00 target price on the stock.
Verint Systems (NASDAQ:VRNT) had its buy rating reissued by analysts at Oppenheimer Holdings, Inc.. The firm currently has a $49.00 target price on the stock.
Zymeworks (NASDAQ:ZYME) was downgraded by analysts at Scotiabank from an overweight rating to an underweight rating.
